Whole-genome analysis informs breast cancer response to aromatase inhibitionMatthew J. Ellis, Mark A. Watson, Vera J. Suman et al.|Nature|2012Cited by 1k
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i> -Mutant ER-Positive and HER2-Negative Breast CancerX. Cynthia, Matthew J. Ellis, Vera J. Suman et al.|Clinical Cancer Research|2017Cited by 74